Sökning: onr:"swepub:oai:DiVA.org:oru-11114" >
SCOTROC 2B :
SCOTROC 2B : feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer
-
Clamp, A. R. (författare)
-
Mäenpää, J. (författare)
-
Cruickshank, D. (författare)
-
visa fler...
-
Ledermann, J. (författare)
-
Wilkinson, P. M. (författare)
-
Welch, R. (författare)
-
Chan, S. (författare)
-
Vasey, P. (författare)
-
- Sorbe, Bengt (författare)
- Örebro universitet,Institutionen för klinisk medicin
-
Hindley, A. (författare)
-
Jayson, G. C. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2005-12-13
- 2006
- Engelska.
-
Ingår i: British Journal of Cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 94:1, s. 55-61
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- MEDICINE
- MEDICIN
- Oncology
- Onkologi
- Onkologi
- Oncology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Clamp, A. R.
-
Mäenpää, J.
-
Cruickshank, D.
-
Ledermann, J.
-
Wilkinson, P. M.
-
Welch, R.
-
visa fler...
-
Chan, S.
-
Vasey, P.
-
Sorbe, Bengt
-
Hindley, A.
-
Jayson, G. C.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Örebro universitet